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Abstract
Objectives:	In	a	separate	document,	we	have	provided	specific	guidance	on	perform-
ing	 individual	 pharmacokinetic	 (PK)	 studies	 using	 limited	 samples	 in	 persons	with	
hemophilia	with	the	goal	to	optimize	prophylaxis	with	clotting	factor	concentrates.	
This	paper,	 intended	for	clinicians,	aims	to	describe	how	to	interpret	and	apply	PK	
properties	obtained	in	persons	with	hemophilia.
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Essentials
•	 The	use	of	pharmacokinetics	(PK)	and	population	PK	(PopPK)	in	tailoring	hemophilia	treatment	is	growing	steadily.
•	 We	provide	clinical	guidance	on	uses	and	adoption	of	PK	and	PopPK	in	hemophilia.
•	 We	provide	guidance	on	appraising	PK	reports,	including	studies	and	claims	comparing	different	factor	concentrates.
•	 We	discuss	the	importance	of	large	PK	data	collection	for	advancement	of	hemophilia	treatment	approaches.
1  | INTRODUCTION
The	 goal	 of	 hemophilia	 A	 and	 B	 treatment	 is	 the	 prevention	 of	
bleeding	and	thus	to	minimize	the	consequences	of	bleeding	into	
joints	and	vital	organs,	consequently	enhancing	both	the	expected	
length	and	quality	of	life.1	This	is	usually	achieved	by	regular	pre-
ventive	 intravenous	 administration	 of	 the	 deficient	 coagulation	
factor,	 a	 treatment	 strategy	 called	 prophylaxis.2	 The	 dose	 and	
frequency	 of	 factor	 concentrate	 infusions	 to	 improve	 important	
patient	outcomes,	such	as	a	reduction	in	the	number	and	severity	
of	spontaneous	or	 traumatic	bleeding	episodes	or	a	 reduction	 in	
the	burden	of	care,	vary	largely	among	individuals,	and	may	vary	
in	the	same	individual	over	time.3	This	variability	 is	attributed	to	
many	factors,	first	of	which	is	the	individual’s	tendency	to	bleed.	
This	can	be	referred	to	as	a	pharmacodynamic	(PD)	component	of	
the	process,	 ie,	 the	mechanisms	 linking	 the	plasma	activity	 level	
of	 clotting	 factor	 concentrate	with	 the	 relevant	outcome.	Other	
sources	 of	 variability	 are:	 the	 bleeding	 history,	 including	 recent	
pattern	of	bleeding	as	a	function	of	factor	activity	level	and	pres-
ence	of	target	joints,	level	of	physical	activity,	preferences	with	re-
gard	to	infusion	frequency,	availability	and	affordability	of	clotting	
factor	 concentrates,	 targeted	 or	 tolerated	 annualized	 bleeding	
rate	 and	 the	 individual’s	 specific	pharmacokinetic	 (PK)	profile.4,5 
Accounting	for	each	of	these	causes	of	variability	is	critical	to	in-
dividualizing	treatment.	While	an	understanding	of	an	individual’s	
PK	and	PD	are	equally	important	in	clinical	decision	making,	knowl-
edge	of	 individual	PK	has	slowly	become	a	key	driver	of	person-
alized	hemophilia	therapy.	The	variability	of	the	disposition	of	the	
infused	 clotting	 factor	 concentrate	 (ie,	 the	 specific	 activity-	time	
curve	after	the	infusion)	is	larger	among	different	individuals	than	
Methods:	The	members	of	the	Working	Party	on	population	PK	(PopPK)	of	the	ISTH	
SSC	Subcommittee	on	Factor	VIII	and	IX	and	rare	bleeding	disorders,	together	with	
additional	 hemophilia	 and	 PK	 experts,	 completed	 a	 survey	 and	 ranking	 exercise	
whereby	key	areas	of	interest	in	the	field	were	identified.	The	group	had	regular	web	
conferences	to	refine	the	manuscript’s	scope	and	structure,	taking	into	account	com-
ments	from	the	external	feedback	to	the	earlier	document.
Results:	Many	clinical	decisions	in	hemophilia	are	based	on	some	form	of	explicit	or	
implicit	PK	assessment.	Individual	patient	PK	profiles	can	be	analyzed	through	tradi-
tional	or	PopPK	methods,	with	the	latter	providing	the	advantage	of	fewer	samples	
needing	to	be	collected	on	any	prophylaxis	regimen,	and	without	the	need	the	for	a	
washout	period.	The	most	useful	presentation	of	PK	results	for	clinical	decision	mak-
ing	are	a	curve	of	the	factor	activity	level	over	time,	the	time	to	achieve	a	certain	ac-
tivity	level,	or	related	parameters	like	half-	life	or	exposure	(AUC).	Software	platforms	
have	been	developed	to	deliver	this	information	to	clinicians	at	the	point	of	care.	Key	
characteristics	of	studies	measuring	average	PK	parameters	were	reviewed,	outlining	
what	makes	a	credible	head-	to-	head	comparison	among	different	concentrates.	Large	
data	collections	of	PK	and	treatment	outcomes	currently	ongoing	will	advance	care	in	
the	future.
Conclusions:	Traditionally	used	to	compare	different	concentrates,	PK	can	support	
tailoring	of	hemophilia	treatment	by	individual	profiling,	which	is	greatly	simplified	by	
adopting	a	PopPK/Bayesian	method	and	limited	sampling	protocol.
K E Y W O R D S
factor	IX,	factor	VIII,	population	pharmacokinetics,	tailored	prophylaxis,	tailoring
     |  537IORIO et al.
within	an	individual	over	time	or	across	different	concentrates	of	
the	 same	class.6,7	Therefore,	 assessing	 the	 individual	 disposition	
of	the	infused	concentrate	for	each	specific	patient	should	be	con-
sidered	as	a	primary	objective	 in	tailoring	prophylaxis	to	 individ-
ual	needs.8	Whereas	PK	does	not	set	optimal	thresholds	or	define	
patient	 needs,	 tailoring	 treatment	 to	 individual	 characteristics,	
changes	 in	 lifestyle	and	 response	 to	clinical	 events	using	a	 “trial	
and	error”	approach	without	the	knowledge	of	individual	PK	yields	
suboptimal	results.
The	primary	aim	of	this	article	is	to	describe	how	PK	analyses	in	
persons	with	hemophilia,	using	a	proposed	common	terminology,	are	
currently	interpreted	and	applied	while	considering	the	recommen-
dations	of	the	ISTH.
2  | MANUSCRIPT DEVELOPMENT  
WORKFLOW
This	 manuscript	 is	 the	 result	 of	 the	 collaborative	 effort	 of	 the	
working	 party	 on	 Population	 Pharmacokinetics	 of	 the	 Scientific	
Standardization	 Committee	 (SSC)	 of	 the	 International	 Society	 for	
Thrombosis	 and	 Hemostasis	 (https://www.isth.org/members/
group.aspx?id=100348).	The	group	was	established	in	July	2015	and	
met	regularly	through	June	2017	to	establish	recommendations	for	
performing	individual	PK	assessments	adopting	a	PopPK	approach.	
These	 recommendations	 can	 be	 found	 in	 Iorio	 et	al.9	 The	 present	
document,	although	not	an	official	communication	of	the	SSC,	elab-
orates	 on	 pharmacokinetics	 in	 hemophilia	 beyond	 what	 could	 be	
addressed	in	Iorio	et	al.9	Open	comments	from	experts	in	the	field	
of	 coagulation	 factor	 concentrates	 PK	 (independent	 investigators,	
pharmaceutical	 company	 PK	 experts,	 and	 members	 of	 regulatory	
bodies)	were	invited	beyond	the	original	Working	Party	membership.
3 | THE EMPIRICAL APPROACH TO DOSING 
CLOTTING FACTOR CONCENTRATES IN PERSONS 
WITH HEMOPHILIA
Dosing	guidance	for	clotting	factor	concentrate	replacement	tends	
to	provide	flexibility	to	the	treater	in	response	to	the	known	PK	vari-
ability	amongst	persons	with	hemophilia.	Using	prophylaxis	with	a	
standard	 half-	life	 factor	 VIII	 concentrate	 as	 an	 example,	 a	 typical	
dosing	regimen	would	be	20	to	40	IU/kg	administered	every	other	
day.	Assuming	a	recovery	of	0.02	IU/mL	(ie.	2	IU/dL)	for	each	1	IU/
kg	of	 infused	factor	VIII	and	an	average	half-	life	of	12	h,	 this	 regi-
men	would	provide	the	“average”	persons	with	hemophilia	a	trough	
level	at	or	above	0.01	IU/mL.	This	 “one-	size-	fits-	all”	dosing	usually	
requires	doses	to	be	titrated	within	the	dose	range	by	use	of	blood	
sampling	and	empirical	methods	for	individualization.	This	“trial	and	
error”	approach	is	commonly	applied	in	practice.
When	 looking	 across	 classes	 of	 concentrates,	 the	 way	 that	
concentrate-	specific	PK	properties	are	accounted	for	 is	 in	the	rec-
ommended	starting	regimens	for	the	phase	III	studies.	For	example,	
50	IU/kg	 twice	 a	 week	 or	 100	IU/kg	 weekly	 for	 a	 standard	 half-	
life	 recombinant	 factor	 IX	 concentrate	 (rFIX),	 or	 100	IU/kg	 every	
10	days	for	an	extended	half-	life	(EHL)	product,	are	all	 intended	to	
target	a	given	trough	level.	In	practice,	irrespective	of	which	starting	
regimen	is	chosen,	the	range	of	doses	and	intervals	that	patients	are	
ultimately	on	varies	widely,	implying	that	during	titration,	some	pa-
tients	will	be	under-	or	over-	dosed.
Furthermore,	 this	 “population	 average”	 approach	 does	 not	 ac-
count	 for	patient	variables	such	as	age,	Body	Mass	 Index	 (BMI)	or	
blood	group	that	are	already	known	to	affect	PK.10–12	Thus,	the	pop-
ulation	average	and	subsequent	“trial	and	error”	approach	to	dosing	
does	not	incorporate	current	knowledge	and	available	PK	modeling	
and	simulation	tools.
4  | ESTABLISHED USES OF PK 
MEASURES IN ROUTINE CLINICAL 
CARE OF PERSONS WITH 
HEMOPHILIA AND THEIR LIMITATIONS
The	use	of	any	measurement	of	postinfusion	plasma	activity	level	can	
be	considered	a	basic	application	of	PK	to	the	treatment	of	hemo-
philia.	The	three	most	established	measurements	are:	(i)	the	measure-
ment	of	 trough	 levels	during	prophylactic	 treatment,	 (ii)	measuring	
peak	and	trough	in	a	perioperative	setting,	or	(iii)	recovery	and	half-	
life	as	guidance	to	wean	off	immune	tolerance	induction	(ITI).
In	routine	prophylaxis,	the	classical	approach	to	monitoring	patients	
is	to	have	their	plasma	factor	activity	levels	measured	just	prior	to	the	
next	infusion	or,	in	other	words,	the	trough	level.	This	is	to	ensure	that	
the	plasma	activity	 level	of	 the	 infused	 factor	 is	 still	 above	 the	 level	
considered	critical	to	prevent	bleeding.13	This	critical	threshold	is	often	
assumed	 to	 be	 0.01	IU/mL	 although	 different	 thresholds	 have	 been	
proposed	for	differing	levels	of	physical	activity	or	tendency	to	bleed.3 
Dose	adjustment	based	on	measurement	of	pre-	dose	(trough)	levels	is	a	
simplified	and	empirical	PK-	guided	approach	to	prescribing	prophylaxis.
To	 ensure	 bleeding	 control	 during	 surgery,	 national	 and	 inter-
national	 guidelines	 recommend	 maintaining	 plasma	 activity	 levels	
of	 factor	concentrates	above	specific	 thresholds	 for	specific	dura-
tions	 of	 time,	 both	 of	which	 depend	 on	 the	 type	 of	 surgery.14	 As	
a	 result,	 persons	 with	 hemophilia	 undergoing	 surgery	 often	 have	
one	or	more	plasma	factor	activity	levels	measured	to	ensure	opti-
mal	levels	are	maintained.15	Perisurgical	dose	adjustment	based	on	
these	measurements	can	be	considered	a	simplified	and	empirical	PK	
guided	approach	to	bleeding	prevention.	Similarly,	when	perisurgi-
cal	hemostasis	is	obtained	by	using	a	continuous	infusion	of	clotting	
factor	concentrate,	the	initial	infusion	rate	can	be	calculated	based	
on	the	anticipated	clearance	of	the	concentrate	itself.	It	has	been	ob-
served,	however,	in	a	large	surgery	study	using	these	methods	that	
the	majority	of	levels	continue	to	be	outside	of	the	targeted	range.16 
Recently,	a	population	PK	(PopPK)	approach	to	perisurgical	dosing	
has	been	proposed,17	and	a	randomized	controlled	trial	is	currently	
ongoing	 to	 evaluate	 this	 approach	 to	 individualized	 dosing	 in	 the	
perisurgical	setting.18
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Defining	 tolerance	 in	 the	 context	 of	 an	 ITI	 regimen	 after	 the	
inhibitor	 is	 no	 longer	 detectable	 with	 the	 Bethesda	 assay	 (ideally	
the	Nijmegen	method),	 requires	monitoring	 of	 the	 recovery	 of	 in-
fused	factor	VIII	and	then	 its	half-	life.	Specific	 thresholds	are	sug-
gested	for	both	outcomes	to	define	success	or	partial	success.19–22 
Very	recently,	a	more	pragmatic	application	of	PK	to	tailor	the	dose	
during	ITI	in	children	was	suggested	by	the	UK	Haemophilia	Centre	
Doctors’	Organisation	 (UKHCDO)	 that	 uses	 only	 trough	 level	 and	
mitigates	the	need	to	take	multiple	samples	to	assess	both	recovery	
and	half-	life.23	Calculating	the	half-	life	or	measuring	the	recovery	or	
trough	 level	of	 the	 infused	 factor	constitutes	a	 (simplified)	PK	ap-
proach	to	tailoring	individual	treatment.
5  | THE IMPORTANCE OF RELIABLE 
LABORATORY MEASUREMENTS
An	important	consideration	when	using	plasma	factor	activity	level	
measurements	 for	 clinical	 purposes	 is	 the	 precision	 and	 accuracy	
of	the	laboratory	measurements.	There	is	robust	evidence	that	the	
choice	of	assay	type	(ie,	one-	stage	versus	chromogenic),	the	choice	
of	 aPTT	 reagent,	 as	well	 as	 the	 choice	 of	 reference	 standard	 (ge-
neric	versus	concentrate	specific)	 impacts	the	measurement	result	
in	a	significant	way.14,24	According	to	the	general	theory	of	measure-
ments,	 the	variability	attributed	to	the	measurement	methods	 (eg,	
when	using	different	assays	on	the	same	plasma	sample)	 is	due	to	
random	or	systematic	measurement	errors.25,26
The	random	error	translates	into	imprecision	or	variation.	A	typ-
ical	 coefficient	of	variation	of	measurements	 for	clotting	assays	 is	
equal	to	or	below	15%	that	results	in,	for	example,	a	measurement	
of	 0.50	IU/mL,	 if	 repeated	 multiple	 times,	 giving	 results	 between	
0.43	IU/mL	to	0.57	IU/mL	two-	thirds	of	the	time.
The	systematic	error	 translates	 into	poor	accuracy	or	 signifi-
cant	deviation	from	the	true	value.	For	example,	a	test	based	on	
a	specific	reagent	will	systematically	report	a	lower	or	higher	re-
sult	 than	 another	 reagent.	 Systematic	 errors	 can	 also	 apply	 to	 a	
combination	of	specific	concentrates	and	specific	assays.	A	typical	
example	 is	the	finding	that	the	original	 formulation	of	B-	Domain	
deleted	factor	VIII	had	a	lower	than	expected	recovery	when	mea-
sured	with	a	one	stage	clotting	assay	using	a	full	length	factor	VIII	
as	a	reference	standard,	but	not	when	using	a	B-	Domain	deleted	
specific	 standard.27,28	 This	 also	 seems	 to	 be	 relevant	 for	 some	
wild	type	and	modified	recombinant	and	plasma-	derived	FVIII	and	
FIX	products,29–31	specifically	where	the	one-	stage	clotting	assay	
result	 is	 influenced	by	 the	aPTT	 reagent	 selected.32	A	 review	of	
the	current	evidence	about	the	performance	of	different	reagents	
for	 different	 factor	 concentrates	 has	 been	 performed	 by	 Young	
and	colleagues.33	Manufacturers	are	responsible	for	providing	in-
formation	to	clinical	 laboratories	on	appropriate	assay	and	assay	
conditions	 for	 their	 product	 and	 can	 support	 efforts	 to	 ensure	
measurement	accuracy	when	a	single	assay	is	used	in	the	labora-
tory	across	a	number	of	different	products.32	While	the	one-	stage	
clotting	assay	is	most	commonly	used	for	clinical	monitoring,	there	
is	a	move	towards	adoption	of	the	chromogenic	assay,	which	tends	
to	be	less	prone	to	systematic	errors.34
As	 recommended	 in	 the	 guidance,9	 any	 measurement	 that	 is	
below	the	limit	of	quantification	(BLQ)	of	the	specific	assay	should	
be	reported	(eg,	<0.01	IU/mL	and	not	0	IU/mL	or	0.01	IU/mL).	When	
BLQs	are	removed	from	the	PK	modeling	process,	the	resulting	half-	
life	will	 be	overestimated	 (ie,	 longer	 than	 if	 the	model	 used	 these	
values)35	resulting	in	a	potentially	unsafe	reduction	in	dose	or	exten-
sion	of	frequency.	Nevertheless,	a	number	of	methods	are	available	
for	using	BLQs	in	PopPK	analyses.36	Avoiding	sampling	times	where	
BLQ	levels	are	expected	is	also	good	practice.
6  | DOSE INDIVIDUALIZATION BASED ON 
ESTIMATION OF INDIVIDUAL PK PROFILES
Owing	to	the	wide	variability	in	factor	concentrate	PK	between	per-
sons	with	hemophilia,	assessing	and	using	individual	PK	knowledge	
for	dosing	is	an	attractive	option	over	the	“trial	and	error”	methods	
as	described	above	and	has	been	found	to	reduce	factor	concentrate	
usage	and	bleeding	events	as	compared	to	standard	prophylaxis.37,38 
In	addition,	utilization	of	a	PopPK	method	to	derive	individual	PK	pa-
rameters	will	contribute	significantly	to	individualized	treatment	of	
persons	with	hemophilia.	To	facilitate	understanding	this	potential	
we	will	compare	and	contrast	it	to	the	traditional	approach.
6.1 | Traditional approach to obtaining individual PK 
information and its disadvantages
All	non-	empirical	(ie,	non–”trial	and	error”)	approaches	to	calculate	
an	 individual	dose	 require	 some	assessment	of	 the	 individuals’	PK	
parameters.	A	publication	of	the	International	Society	of	Thrombosis	
and	Hemostasis	(ISTH)	in	200139	recommends	10	to	11	postinfusion	
samples	following	a	washout	period	with	subsequent	PK	modeling	to	
obtain	PK	parameter	estimates.	While	the	aim	of	the	guideline	was	
to	understand	the	PK	of	a	specific	factor	concentrate	in	a	population	
of	12	 to	15	persons	with	hemophilia,	 the	suggested	PK	study	can	
also	be	used	as	a	means	to	generate	individual	PK	estimates	for	use	
in	 dosing	 guidance.	 Some	 tailored	 prophylaxis	 programs	 based	on	
a	similar	method	are	currently	ongoing.37	However,	all	 such	previ-
ously	published	approaches	share	some	common	limitations:	usually	
using	a	standard	test	dose	(eg,	50	IU/kg)	and	requiring	a	wash-	out	
period,	which	 is	potentially	risky	for	patients,	as	well	as	numerous	
postinfusion	samples,	over	a	period	of	days,	which	 is	burdensome	
and	impractical	for	many	patients,	especially	children.
6.2 | PopPK approach and Bayesian estimation to 
obtaining individual PK information
Determination	 of	 individual	 PK	 parameters	 can	 be	 achieved	 with	
fewer	 samples	 than	 the	 traditional	 approach	 through	 integration	
of	 information	 from	 both	 a	 patient	 population	 and	 an	 individual.	
Limited-	sampling	models	 (LSM)	 that	 rely	 on	1	 to	3	 blood	 samples	
     |  539IORIO et al.
have	been	primarily	used	for	the	estimation	of	area	under	the	curve	
(AUC)	and	maximum	plasma	concentration	(Cmax).40,41	The	Bayesian	
approach,	which	 is	based	on	Bayes’	 theorem,	has	been	used	 for	 a	
wide	 variety	 of	 drugs	 to	 predict	 individual	 PK	 parameters	 from	 1	
to	4	blood	samples.42–45	With	these	methods,	 there	 is	an	underly-
ing	assessment	of	the	dose-	exposure	relationship	and	the	relevant	
covariates	that	modify	this	relationship	such	as	age	or	weight	from	
a	patient	population.	Coupled	with	patient	 specific	 covariates	 and	
drug	levels	in	blood,	the	models	integrate	population	and	individual	
level	 information	 to	 derive	 individual	 PK	 parameters	 that	 can	 be	
used	to	derive	an	individual	PK	profile.
Population	level	PK	information	can	be	analyzed	and	understood	
using	PopPK	methods	that	employ	non-	linear	mixed	effect	models.	
In	hemophilia,	PopPK	uses	both	dense	and	sparse	PK	data	from	per-
sons	with	hemophilia	in	either	the	presence	or	absence	of	a	washout	
to	derive	a	unique	understanding	of	inter-	individual	variability	(IIV)	
and	its	predictors	(eg,	age,	weight,	BMI,	blood	group),	inter-	occasion	
variability	(IOV)	that	defines	how	an	individual	patients’	PK	changes	
over	time,	and	left-	over	or	residual	variability.46	One	goal	of	a	PopPK	
model	 is	 to	use	 the	derived	 relationships	between	PK	and	patient	
characteristics	(eg,	age,	weight,	BMI,	blood	group)	to	predict	PK	in	
the	next	 individual	 in	 the	absence	of	 individual	 factor	activity	 lev-
els.	An	extension	of	 this	and	 the	method	recommended	on	behalf	
of	the	ISTH	SSC	on	FVIII	and	FIX,9	is	to	use	an	appropriately	derived	
PopPK	model	and	Bayesian	estimation	techniques	to	predict	individ-
ual	PK	parameters	using	patient-	specific	characteristics	plus	patient-	
measured	FVIII	or	FIX	activity	levels.
The	characteristics	of	PK	variability	of	clotting	factor	concentrates	
are	especially	suited	to	this	dose	individualization	technique.	In	gen-
eral,	the	variability	in	the	dose-	exposure	relationship	is	judged	against	
the	therapeutic	window	of	a	drug	where	the	variability	is	considered	
large	or	clinically	relevant	when	it	places	different	patients	(IIV),	or	the	
same	patient	over	 time	 (IOV),	outside	of	 the	 therapeutic	window.47 
When	the	therapeutic	window	is	large,	PK	variability	is	less	important	
F IGURE  1  Impact	of	sources	of	variability	in	drug	disposition	and	the	impact	of	individualized	dosing.	The	plot	describes	repeated	
measurements	of	drug	concentrations	in	patients	over	time.	The	red,	blue,	and	green	dots	for	a	given	patient	indicates	three	measurements	
for	that	patient	at	different	times.	The	greyed-	out	area	represents	the	therapeutic	window.	Panel	A	describes	that	when	the	therapeutic	
window	is	larger	than	the	variability	among	(IIV)	and	within	(IOV)	patients,	patients	have	therapeutic	concentrations	most	of	the	time.	In	
this	case,	an	average	dose	(either	as	a	fixed	dose	or	a	weight-	adjusted	dose)	is	expected	to	be	therapeutic	in	most	patients	most	of	the	time.	
Panel	B	describes	a	drug	producing	the	same	measurements	as	in	Panel	A	but	having	a	narrower	therapeutic	window.	In	this	case,	IIV	and	
IOV	are	large	relative	to	the	therapeutic	window	and	the	relevant	patient	dose	will	need	to	differ	amongst	patients	as	well	as	within	the	
same	patient	over	time.	Panel	C	describes	the	situation	where,	relative	to	the	therapeutic	window,	the	IIV	is	large	and	the	IOV	is	small.	In	
this	case,	deriving	an	individual	dose	from	an	assessment	of	individual	PK	will	maintain	the	patient	at	therapeutic	concentrations	over	time	
because	their	PK	is	stable	(low	IOV).	This	is	the	case	for	FVIII	and	FIX	in	persons	with	hemophilia.	Panel	D	presents	an	example	of	adjusting	
the	dose	based	on	individual	PK	assessment	following	occasion	1	with	subsequent	occasions	falling	in	the	therapeutic	range.	This	is	the	
concept	of	individualized	dosing	of	factor	concentrates	in	persons	with	hemophilia
A B C D E F G
Subject
Co
nc
en
tra
tio
n
Therapeutic
window
Occasion 1
Occasion 2
Occasion 3
A B C D E F G
Subject
Co
nc
en
tra
tio
n
Therapeutic
window
Occasion 1
Occasion 2
Occasion 3
A B C D E F G
Subject
Co
nc
en
tra
tio
n
Therapeutic
window
Occasion 1
Occasion 2
Occasion 3
A B C D E F G
Subject
Co
nc
en
tra
tio
n
Therapeutic
window
Occasion 1
Occasion 2
Occasion 3
Dose modified based on occasion 1
Occasion 2
Occasion 3
After PK based
dose adjustment
Panel (A)
Panel (B) Panel (D)
Panel (C)
540  |     IORIO et al.
to	attaining	target	activity	levels	(Figure	1,	panel	A)	than	when	there	
is	a	narrow	therapeutic	window	(Figure	1,	panel	B).	Indeed,	when	PK	
variability	 is	 small	 in	 relation	 to	 the	 therapeutic	 window	 (Figure	1,	
panel	A),	the	disposition	of	a	specific	dosage	of	a	drug	(either	as	fixed	
dose	or	weight	adjusted	dose)	can	be	predicted	for	most	individuals	in	
a	population,	or,	more	precisely,	it	can	be	predicted	that	most	individu-
als	will	have	their	plasma	activity	levels	within	the	therapeutic	window.	
This	is	the	case	for	many	drugs,	especially	over-	the-	counter	drugs,	and	
is	an	ideal	situation.	Narrow	therapeutic	window	drugs	that	have	a	rel-
atively	 large	IIV	and	IOV	require	continuous	dose	adjustments,	as	 is	
the	case	of	warfarin,	and	individual	PK	understanding	is	not	needed	
because	it	is	unable	to	solve	this	large	variability	issue	(Figure	1,	panel	
B).	The	intermediate	scenario,	and	the	one	applying	to	clotting	factor	
concentrates,	is	where,	relative	to	the	therapeutic	window,	the	IIV	is	
large	and	the	IOV	is	small	(Figure	1,	panel	C).	In	this	case,	assessing	the	
individual	PK,	which	changes	minimally	day	over	day	(small	IOV)	but	
greatly	between	patients	(IIV)	allows	for	dose	individualization.	By	ad-
justing	the	dose	for	each	subject,	the	individual	PK	will	be	maintained	
within	the	therapeutic	window	over	time	(Figure	1,	panel	D).
While	IOV	tends	to	be	small	when	the	patient	is	in	a	stable	condi-
tion	meaning	that	their	PK	assessment	remains	valid	over	time,	non-	
stable	conditions	will	necessitate	reassessment	of	PK	to	ensure	that	
dosing	 is	 congruent	with	 condition.	Noteworthy	 examples	 include	
children	where	weight-	normalized	clearance	is	higher	in	young	chil-
dren	and	gradually	reaches	adult	levels	with	increasing	age10	and,	as	
a	result,	reassessment	of	PK	profiles	in	young	children	is	done	every	
two	to	three	years	in	some	centers,	and	can	be	greatly	facilitated	by	
using	a	 limited	sampling	PopPK	approach.	Other	examples	 include	
the	clearance	changes	associated	with	 the	 immediate	postsurgical	
period	 in	patients	 receiving	FVIII/FIX	by	bolus	or	continuous	 infu-
sion	and	in	patients	with	changing	inhibitor	titers	to	FVIII/FIX	on	ITI.	
The	rate	of	change	of	PK	within	a	patient	in	non-	stable	conditions	is	
unique	to	the	patient	and	condition.	Specially	constructed	sampling	
schedules	and	PopPK	programs	for	these	various	clinical	scenarios	
are	an	area	of	active	research.18
6.3 | Limitations to PopPK individual profiling
As	with	 all	 regression	models,	 the	 predictive	 accuracy	of	 a	model	
outside	of	the	covariate	space	(eg,	age,	weight,	inhibitor	status)	used	
for	model	development	is	uncertain.	This	was	demonstrated	when	a	
previously	derived	FVIII	model10	was	used	to	predict	PK	in	a	cohort	
of	persons	with	hemophilia	undergoing	surgery.17 Since the model 
was	 not	 built	 on	 patients	 during	 surgery,	 it	 was	 not	 an	 accurate	
predictor	in	that	scenario	and	a	surgery	specific	PopPK	model	was	
built.	Other	important	scenarios	in	hemophilia	where	PopPK	models	
could	be	built	if	enough	data	were	available,	includes	patients	with	
inhibitors,	 the	obese,	 and	children.	Regardless	of	 the	 scenario,	we	
do	not	yet	know	how	many	patients	are	sufficient	to	build	a	predic-
tive	 brand-	specific	 PopPK	model	 best	 suited	 for	Bayesian	 estima-
tion.	Large	data	collections,	such	as	the	Web-	Accessible	Population	
Pharmacokinetics	 Service–Hemophilia	 (WAPPS-	Hemo),48 aim to 
gather	 FVIII	 and	 FIX	 data	 from	 thousands	 of	 patients	 on	 various	
brands	in	order	to	develop	PopPK	models	that	span	the	entirety	of	
the	 covariate	 space,	 better	 representing	 persons	 with	 hemophilia	
than	clinical	trial	participants.	Prospective	evaluation	of	the	devel-
oped	models	is	also	possible	and	future	research	will	address	these	
limitations	more	robustly	to	further	inform	practice.
Given	 densely	 sampled	 profiles,	 traditional	 noncompartmental	
analysis	 produces	 PK	 estimates	 equivalent	 to	 PopPK	 estimates.49 
Bayesian	forecasting	of	individual	PK	having	a	set	of	limited	patient	
activity	levels	has	an	uncertainty	that	is	tied	to	the	number	and	tim-
ing	of	 those	 samples.50	Brekken	et	al.50	 demonstrated	 that	 if	 only	
two	samples	were	taken	for	plasma-	derived	FIX,	there	is	greater	pre-
cision	of	the	estimates	when	those	two	samples	are	taken	at	the	end	
of	the	profile	(day	4)	vs	at	the	beginning	of	the	profile	(day	2)	with	
the	caveat	that	imprecision	increases	when	samples	are	BLQ,	which	
tends	to	be	at	the	end	of	the	profile.	The	ISTH	guidance	aims	to	re-
duce	this	uncertainty	by	providing	instruction	to	clinicians	on	timing	
and	number	of	samples.9
A	limitation	to	the	use	of	PK	and	PopPK	is	in	instances	of	a	dis-
cordance	between	concentrate	activity	 in	blood	and	response	 (eg,	
bleeding),	 where	 PD	 plays	 a	 more	 important	 role.	 For	 example,	
plasma	 FIX	 activity	 levels	may	 represent	 a	 suboptimal	marker	 for	
clinical	 efficacy,51	 and	data	 for	different	FIX	products	may	not	be	
directly	comparable.51	The	techniques	applied	in	order	to	extend	the	
half-	life	(EHL)	of	rFIX	using	pegylation,	albumin	fusion	or	Fc	fusion,	
makes	the	EHL	rFIX	products	substantially	different	on	a	molecular	
level,	 presumably	 affecting	 their	 extravascular	 distribution,	 which	
translates	into	differing	PK	characteristics	as	well	as	differences	in	
the	 relationship	between	measured	plasma	FIX	 activity	 levels	 and	
clinical	outcome.	Knowledge	of	individual	PK	in	isolation	of	the	in-
dividual	activity-	response	relationship	(PD)	is	unlikely	to	lead	to	op-
timal treatment.
Another	 limitation	of	a	PK	and	PopPK	tailored	approach	 is	pa-
tient	and	treater	acceptance.	A	formal	analysis	of	patient	and	treater	
attitudes	towards	PK-	tailored	prophylaxis	from	both	low-	and	high-	
income	countries	was	completed	and	showed	 that	 the	majority	of	
patients	and,	to	a	greater	extent,	treaters	would	be	willing	to	switch	
to	 PK-	tailored	 dosing.52	 This	 was	 not	 without	 hesitation	 where	
daily	 dosing	 was	 a	 barrier	 unless	 bleeding	 frequency	 was	 greatly	
reduced.	 It	was	 interesting	 to	note	 that	 number	of	 blood	 samples	
and	 frequency	of	 sampling	 for	PK	estimation	were	not	barriers	 to	
acceptance52	suggesting	that	follow-	up	samples	for	verification	of	a	
new	regimen	would	be	feasible.	While	resource	rich	countries	using	
high	 dose	 prophylaxis	 (20-	40	IU/kg	Q48	h)	may	 use	 a	 PK-	tailored	
approach	to	reduce	costs,	resource	poorer	countries	using	low	dose	
prophylaxis	(6-	10	IU/kg	twice	weekly)	may	use	PK-	tailoring	to	opti-
mize	 their	 limited	 resources	 (eg,	 guide	 administration	 around	high	
risk	activities).
Finally,	a	practical	 limitation	to	the	adoption	of	a	PopPK	based	
tailoring	 approach	 is	 the	 complexity	 of	 performing	 a	 post-	hoc	
Bayesian	estimation.	 Indeed,	 this	 is	beyond	what	most	hemophilia	
treatment	 centers	 may	 accomplish	 and	 was	 the	 main	 driver	 for	
developing	WAPPS-	Hemo.	 It	 is	 worth	 noting	 that,	 whereas	 other	
generic	 PopPK	 software	 (eg,	 Doseme	 LLC,	 Taringa	Qld,	 Australia,	
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doseme.com.au;	InsightRX,	Inc.	San	Francisco,	CA,	USA,	insight-	rx.
com;	 TDMx,	 University	 of	 Hamburg,	 Hamburg,	 Germany,	 www.
tdmx.eu)	and	specialized	dedicated	software	classified	as	a	medical	
device	(eg,	my	PKFit,	Shire	Pharmaceutical	Holdings	Ireland	Limited,	
Dublin,	 Ireland,	 www.mypkfit.com)	 exist,	 the	 former	 requires	 a	
significant	 time	commitment	and	expertise.	The	 latter	are	product	
specific	and	heavily	constrained	 in	 their	estimation	and	simulation	
capacity	by	the	need	to	adhere	to	the	labelling	specifications	of	the	
products	 they	 serve.	Defining	WAPPS	 as	 a	 collaborative	 research	
network	was	a	decision	taken	after	multiple	informal	and	formal	con-
sultation	with	relevant	regulatory	agencies.	This	decision	seems	to	
have	preserved	the	capacity	of	WAPPS	to	fully	model	the	observed	
variability,	empowering	and	not	limiting	the	capacity	of	hemophilia	
doctors	to	exercise	their	clinical	judgement.
6.4 | Characteristics of a clinically useful individual 
PK profile
Irrespective	of	the	underlying	PK	method	and	assumptions,	a	clinically	
useful	PK	profile	of	an	individual	patient	must	provide	at	a	minimum:	(i)	
the	predicted	plasma	activity	level	at	any	given	time,	and	(ii)	a	measure	
of	precision	of	 the	estimates.	Coupled	with	patient-	specific	 thresh-
olds,	the	individual	plasma	activity	level	vs.	time	profile	contains	the	
required	 information	needed	 to	 identify	when	 to	 reinfuse	a	patient	
(eg,	target	trough	>	0.03	IU/mL)	or	when	the	risk	of	bleeding	would	be	
low	(eg,	level	>	0.12	IU/mL53).	It	includes	the	predicted	plasma	activ-
ity	 level	at	any	given	time,	or,	as	alternate	display,	 the	time	elapsed	
from	the	infusion	to	any	level	of	interest	with	associated	uncertainty	
(Figure	2,	 panel	A).	 The	 time	 to	 critical	 activity	 level	 is	 increasingly	
reported	as	a	relevant	outcome	measure	 in	PopPK	papers	of	factor	
concentrates.54–56	In	the	event	of	a	change	in	dose	or	frequency,	a	PK	
profile	presenting	the	new	regimen	can	be	calculated	using	the	indi-
viduals’	PK	estimates	(Figure	2,	panel	B	and	C),	and	again	provide	all	of	
the	information	needed	for	clinical	decision	making.	Indeed,	whereas	
an	individual’s	primary	PK	parameters	such	as	clearance	and	volume	
of	distribution	are	important	for	derivation	of	a	PK	profile,	they	are	
usually	not	meaningful	to	clinicians.	Even	secondary	PK	parameters,	
like	individual	terminal	half-	life	and	AUC,	are	more	translatable	to	clin-
ical	practice,	but	still	too	complicated	for	many	clinicians.	Independent	
interpretation	and	use	of	relevant	PK	outcomes	is	beyond	reach	for	
most	 clinics,	 and	 there	 is	 a	move	 towards	embracing	 software	 that	
both	calculates	an	individual’s	PK	profile	using	Bayesian	methods	and	
allows	for	individualized	dose	regimen	design.48	Mobile	applications	
that	extend	the	software	scope	and	allow	the	patient	access	to	their	
predicted	activities	in	real	time	are	currently	under	development.
7  | PK AND POPPK CONTRIBUTION 
TO CHOOSING A SPECIFIC 
FACTOR CONCENTRATE
We	 have	 demonstrated	 that	 knowledge	 of	 one’s	 PK	 profile	 is	
needed	 to	 optimize	 an	 individual	 dosing	 regimen.	 But	 is	 there	
value	 in	 knowing	 concentrate	 specific	 “average”	 PK	 characteris-
tics?	The	theoretical	answer	is	yes.	A	concentrate	with	lower	aver-
age	clearance,	higher	average	exposure	(ie,	AUC/Dose)	and	longer	
average	terminal	half-	life,	is	more	likely	to	yield	favorable	profiles,	
on	average,	in	the	population.	Practically,	a	robust	comparison	of	
PK	across	different	concentrates	is	not	trivial,	and	requires	certain	
critical	considerations	in	appraising	scientific	evidence	in	the	field	
(Table	1).	The	single	most	important	concept	is	that	there	is	more	
variability	among	individuals	(the	population)	than	among	concen-
trates	(the	treatment).6	There	are	two	important	consequences	to	
this	concept:	 the	first	 is	 the	need	to	check	 if	 the	studies	provid-
ing	 the	PK	estimates	have	been	performed	on	populations	com-
parable	to	the	patients	we	are	planning	to	apply	those	results	to	
(ie,	external	validity).57	The	second	is	that	when	we	compare	the	
average	PK	characteristics	of	two	or	more	concentrates,	we	need	
to	 make	 sure	 the	 tested	 populations	 and	 the	 study	 designs	 are	
comparable	and	 robust	enough.	The	most	efficient	 study	design	
to	ensure	comparability	 is	 the	crossover	 study,	where	each	 indi-
vidual	 receives	each	concentrate	and	 they	 therefore	act	as	 their	
own control.39	Of	 critical	 importance	 is	 comparing	only	PK	data	
generated	with	 comparable	methods:	 too	 often,	 and	 sometimes	
even	 in	 crossover	 studies,	 different	 assumptions	 and	 methods	
(including	sampling	schedules)	are	used	for	the	two	concentrates	
under	comparison,	and	the	method	more	than	the	concentrates	is	
responsible	 for	 the	observed	difference.58–61	 Irrespective	of	 the	
goodness	of	the	decision-	making	process	and	quality	of	the	sup-
portive	evidence,	generic	 choices	at	 the	population	 level	 cannot	
substitute	 for	 individual	PK	profiling,	as	 they	do	not	account	 for	
inter-	patient	variability.
8  | PARTICIPATING IN LARGE PRAGMATIC 
POPPK DATA COLLECTIONS
Until	 recently,	 the	 vast	 majority	 of	 PK	 and	 PopPK	 studies	 have	
been	 performed	 by	 drug	manufacturers	 to	 support	 the	 filing	 of	
regulatory	 applications	 or	 by	 a	 few	 specialized	 research	 centers	
keen	in	using	PK	to	tailor	treatment.6,10,50,54,62	These	studies	have	
also	been	completed	to	control	or	compare	cost	of	different	con-
centrates	 or	 regimens63–65	 and	 to	 develop	 new	 PK	 applications	
to	hemophilia.6,50	PK	 is	now	becoming	more	often	considered	 in	
decision	 making	 in	 hemophilia.	 This	 has	 been	 precipitated	 by	 a	
higher	 usage	 and	 capability	 of	web-	based	 applications,	more	 in-
tense	international	research	collaboration,	 larger	number	of	con-
centrates	competing	on	the	market,	 the	advent	of	EHL	products	
and	 the	 continuous	 pressure	 on	 fair	 use	 of	 resources,	 including	
tendering	processes.	In	this	era	of	large	web-	based	databases	used	
to	 support	 day-	to-	day	 management	 of	 hemophilia	 including	 the	
UKHCDO	database	(www.ukhcdo.org),	the	American	Thrombosis	
&	 Hemostasis	 Network	 (ATHN)	 (www.athn.org),	 the	 Australian-	
Canadian	Bleeding	Disorders	Registry	(ABDR	[www.blood.gov.au/
abdr]/CBDR	 [www.cbdr.ca])	 family	 of	 products,	 the	 FranceCoag	
database	 (www.francecoag.org),	 and	 the	 newly	 launched	World	
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F IGURE  2 Characteristics	and	information	content	of	an	individual	PK	profile.	The	individual	plasma	activity	level	vs.	time	profile	contains	
most	of	the	information	needed	to	identify	the	dose	and	interval	for	the	optimal	regimen	for	a	specific	patient.	We	are	using	as	an	example	plots	
produced	with	WAPPS-	Hemo	(www.wapps-hemo.ca).	Panel	A	represents	a	profile	from	a	simulated	patient	dosed	with	2500	IU	FVIII	and	plasma	
activity	levels	measured	at	4,	24,	and	48	h	post-	administration	(small	hollow	circles	and	interpolated	line).	Using	a	PopPK	model	and	a	Bayesian	
approach	the	fitted	plasma	activity	level	vs	time	profile	is	produced	(solid	black	line)	with	its	associated	uncertainty	(prediction	intervals	as	derived	
from	the	underlying	PopPK	model—dashed	grey	lines).	Estimates	of	terminal	half-	life	and	time	to	threshold	levels	(95%	prediction	intervals)	are	
clinically	actionable	outcomes.	Panel	B	presents	the	process	of	simulation	using	patient	specific	PK.	The	original	measured	plasma	activity	levels	
(red)	and	model	fit	(green)	for	the	2500-	IU	dose	are	presented	for	reference.	For	the	patient	in	Panel	A,	Panel	B	shows	the	weekly	profile	(solid	
blue	line)	on	their	current	regimen	of	2500	IU	infused	every	third	day.	The	trough	was	estimated	at	0.03	IU/mL	with	a	weekly	consumption	of	
5833	IU.	Assuming	a	safety	threshold	of	0.05	IU/mL	for	the	intended	level	of	activity,	the	time	spent	below	0.05	IU/mL	is	estimated	to	be	13	hours	
per	interval.	Panel	C	shows	the	calculated	curve	obtained	by	keeping	the	interval	at	every	third	day,	and	increasing	the	dose	at	4000	IU.	This	
would	increase	the	trough	level	to	0.047	IU/mL	and	the	weekly	consumption	to	9333	IU.	The	time	spent	below	0.05	IU/mL	would	be	2	hours.	
Panel	D	shows	the	calculated	curve	obtained	by	reducing	the	frequency	to	every	second	day	and	the	dose	to	1400	IU.	This	would	increase	the	
trough	level	to	0.05	IU/mL	with	no	time	spent	below	and	the	weekly	consumption	would	be	4900	IU
Time to 0.05 IU/mL = 58 h (51, 65) 
Time to 0.03 IU/mL = 83 h (73, 94)
Time to 0.01 IU/mL = 109 h (95, 123)
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Federation	 of	 Haemophilia	 (WFH)	 Patient	 Registry	 (www.wfh.
org/en/wbdr)	there	is	an	opportunity	to	perform	large	population	
based	 data	 collection	 of	 postinfusion	 plasma	 samples.	 Coupled	
with	PK	approaches,	this	large-	scale	data	could	provide	a	valuable	
contribution	to	clinical	decision	making	at	 the	patient	and	policy	
levels.	Many	centers	have	adopted,	as	routine	clinical	practice,	a	
PopPK	based	individual	estimation	method	using	one	of	the	avail-
able	 PopPK	 applications.48	 This	 is	 feeding	 a	 large	 international	
TABLE  1 Appraisal	of	the	characteristics	of	PK	studies	that	affect	the	comparability	of	results	among	factor	concentrates.	Presented	are	
the	domains	of	a	study	to	be	considered	when	assessing	if	a	study	reporting	a	PK	analysis	can	be	trusted,	applied	to	a	given	clinical	situation,	
or	its	results	compared	to	those	from	another	study.	The	same	criteria	apply	when	assessing	comparative	studies.
Domain Cueing question Characteristic assessed Notes
Population Are the populations used to assess the PK characteristics of the concentrates similar to each other and to the population of 
interest?
Did	the	study	design	and	conduct	control	for	
baseline	imbalance	of	participant	
characteristics?
Study	design Crossover	design	(each	participant	acts	as	
its	own	control);	randomized	trial	(the	two	
arms	are	practically	identical)	.
Did	participants	represent	the	full,	or	at	least	
similar,	spectrum	of	the	population?	Were	the	
demographics	and	clinical	characteristics	of	
the	population(s)	at	baseline	described?
Population	composition The	baseline	characteristics	of	the	
participants	are	usually	described	in	a	
table. 
The	range	of	observed	participant	
characteristics	(eg,	age,	weight)	is	similar	
to	the	population	of	interest.
Was	a	sufficiently	large	sample	enrolled	in	the	
study?
Study	size The	number	of	subjects	is	sufficient	to	
capture	the	variability.	For	a	conventional	
study,	12-	15	subjects	are	deemed	
sufficient;	for	a	population	PK	study	
around	20-	30	subjects	with	dense	data	or	
100	with	sparse	data	are	suggested.
Is	the	precision	of	the	findings	appropriate? Observed	variability The	range	of	observed	PK	values	around	
the	average	is	typical	for	the	population;	
smaller	or	larger	variability	may	require	
careful	consideration.
Is	(are)	the	population(s)	in	the	studies	
representative	of	the	one	I	plan	to	apply	the	
results	to?
External	validity Would	the	patient(s)	I	am	planning	to	apply	
the	results	of	the	study	to	have	been	
enrolled	in	the	study(ies)?
Intervention Did the administration of the concentrates under assessment happen in a similar way across the comparators and with 
respect to the intended use?
Was	the	study	performed	under	routine	clinical	
conditions?
Study	setting Usually	patients	studied	during	regular	
prophylaxis,	in	non-	bleeding	conditions,	
with	exclusion	of	the	surgical	setting.
Were	participants	subject	to	a	wash-	out? Study	design If	no	washout	then	comparisons	should	be	
in	steady-	state	conditions.
Were	the	doses	of	the	concentrates	tested	
comparable?
Study	design PK	of	factor	concentrates	is	supposed	to	be	
dose	independent,	but	use	of	extreme	
doses	may	require	specific	considerations.
Measurements Were the sampling strategies sound and similar across the comparison?
Were	samples	drawn	over	comparable	time	
periods	across	the	comparison?
PK	assessment	method PK	estimates	can	change	depending	on	
how	many	samples	are	used	in	the	
analysis,	and	for	how	long	they	are	
collected.
Were	samples	measured	with	the	same	
laboratory	test	and	reference	standard?
Laboratory	method Using	different	laboratory	tests	and/or	
reference	standard	may	imbalance	the	
comparison.
Were	samples	below	the	limit	of	quantitation	
(BLQ)	recorded?
Laboratory	method Results	for	measurement	below	the	level	of	
detection	must	be	reported	as	“BLQ”	
followed	by	the	minimum	detectable	
concentration.
(Continues)
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database	 and	 has	 been	 integrated	 into	 the	 hemophilia	 manage-
ment	software	used	 in	 the	Czech	Republic,	 the	US,	and	Canada.	
One	of	the	important	advancements	provided	by	these	large	data	
collections	 involves	 the	 simultaneous	 consideration	 of	 clinical	
information,	 such	 as	 bleeding	 and	 treatment	 logs,	 adherence	 in-
formation,	 and	 activity	 levels.	 It	 is	 important	 for	 reliable	 PK	 in-
formation	to	be	stored,	centralized,	and	analyzed	to	enhance	our	
collective	 capacity	 to	 understand	 how	 to	 best	 individualize	 and	
optimize	 the	 treatment	of	persons	with	hemophilia.8	 The	hemo-
philia	community	is	producing	an	impressive	capacity	of	data	col-
lection.	For	example,	 in	 less	than	2	years,	the	180	centers	of	the	
WAPPS	research	network	have	collected	from	>2000	unique	pa-
tients	over	3500	individual	PK	profiles.
9  | CONCLUSIONS
The	use	of	PK	in	the	treatment	of	hemophilia	continues	to	increase	
in	importance	and	studies	have	demonstrated	its	utility.	Along	with	
providing	a	means	to	compare	and	contrast	different	concentrates,	
PK	can	also	be	used	to	aid	in	local	clinical	decision	making.	One	such	
use	is	in	deriving	individual	PK	for	persons	with	hemophilia	to	help	
with	dose	 tailoring	 and	 this	 can	be	 achieved	 through	 a	number	of	
methods.	PopPK	methods	that	integrate	information	from	the	pop-
ulation	 of	 persons	with	 hemophilia	 along	with	 individual	 PK	 infor-
mation	and	characteristics	are	poised	 to	provide	a	convenient	and	
accessible	means	 of	 individualizing	 dose	 tailoring;	 especially	when	
made	 available	 to	 treaters	 and	 patients	 through	 dedicated	 soft-
ware,	albeit	 raising	further	questions	about	appropriate	thresholds	
for	troughs	and/or	peaks	for	participation	in	activities	with	varying	
trauma/bleed	 risk.	Large	data	collection	efforts	are	ongoing	 in	 the	
hemophilia	community	and	this	has	the	potential	to	further	advance	
care.
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Results What are the results? Are they similar, sound and clearly reported across the comparison(s)?
Were	all	expected	results	reported	with	their	
variability?
PK/PopPK	analysis Are	there	any	incomplete	data	reporting	or	
any	selective	outcome	reporting?
Were	results	comparable	with	previous/
contemporary	analyses	on	the	same	
concentrate?
PK/PopPK	analysis Differences	in	the	results	that	cannot	be	
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tion,	intervention	or	analysis	should	be	
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Were	results	comparable	with	those	obtained	
with	other	concentrates	in	the	same	class?
PK/PopPK	analysis Differences	in	the	results	that	cannot	be	
explained	by	differences	in	the	popula-
tion,	intervention,	or	analysis	should	be	
carefully	considered.
Are	clinical	outcomes	presented	in	addition	to	
the	PK?
Study	Design PK/PopPK	studies	are	often	performed	as	
part	of	a	larger	efficacy/safety	study.	
Reporting	(or	referencing)	clinical	
outcomes	might	be	of	help	in	interpreting,	
comparing,	and	applying	the	PK	results.
PK,	pharmacokinetic;	PopPK,	population	pharmacokinetic.
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G LOSSARY OF TERMS
Area under the curve (AUC):	Surface	beneath	 the	activity	vs	 time	
profile;	it	measures	“exposure”	to	the	concentrate.
Baseline factor level:	 The	 level	 of	 factor	 activity	measured	 in	
plasma	 in	 absence	 of	 therapeutically	 administered	 factor	 concen-
trate.	It	is	the	level	of	factor	activity,	if	any,	endogenously	produced	
by	the	individual.	It	is	also	the	factor	level	used	to	classify	the	patient	
as	severe	(<0.01	IU/mL),	moderate	(0.01-	0.05	IU/mL)	or	mild	(>0.05	
IU/mL).
Below limit of quantitation (BLQ):	 Indicates	a	measurement	of	
factor	activity	below	the	minimum	amount	detected	by	the	labora-
tory	assay.	Most	often	BLQ	values	are	reported	as	“undetectable”,	or	
“not	measurable”,	or	<0.01	IU/mL.
Clearance (eg, L/h):	Volume	of	blood	that	is	completely	removed	
of	factor	activity	in	a	specified	unit	of	time.
Extended half-life (EHL):	Recombinant	factor	concentrates	engi-
neered	to	obtain	a	prolonged	exposure	of	the	active	substance	in	the	
plasma.	Extension	of	the	half-	life	is	obtained	by	conjugation	(to	the	
Fc	fragment	of	Ig,	albumin,	or	PEG)	or	other	techniques.
Half-life:	 Time	 required	 for	 the	plasma	activity	 to	decrease	by	
half.	 It	 is	qualified	as	 terminal	half-	life	when	estimated	on	 the	 last	
portion	of	the	activity	versus	time	profile.
Recovery:	Amount	of	factor	activity	measured	in	the	plasma	di-
rectly	 following	an	 infusion	as	a	proportion	of	the	amount	of	con-
centrate	infused.
International Units (IU):	The	unit	used	 to	define	plasma	 factor	
activity	level.	The	normal	range	for	factor	VIII	and	factor	IX	is	from	
0.5	IU/mL	(50	IU/dL)	to	1.5	IU/mL	(150	IU/dL).
Immune tolerance induction treatment (ITI):	Administration	of	
factor	VIII	or	IX	meant	to	induce	tolerance	in	patients	with	inhibitory	
antibodies.
Inter-individual variability (IIV):	 The	 variability	 of	 PK	between	
different	individuals
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Inter-occasion variability (IOV):	The	variability	of	PK	over	time	
within	the	same	individual
Lean body weight:	 Residual	 body	 weight	 after	 subtraction	 of	
the	fat	component	 (equal	or	more	often	 inferior	 to	the	total	body	
weight)
Maximum plasma concentration (Cmax):	 The	 plasma	 factor	 ac-
tivity	measured	after	a	concentrate	 infusion.	For	bolus	 infusions	 it	
should	 theoretically	 be	 the	 concentration	measured	 at	 the	 end	of	
the	infusion	(C0).
Mean residence time (MRT):	The	average	amount	of	time	that	a	
single	molecule	of	factor	VIII	or	factor	IX	stays	in	the	body
Pharmacodynamics (PD):	The	study	of	the	exposure-	response	
relationship	of	a	drug	(ie,	what	the	drug	does	to	the	body).
Pharmacokinetics (PK):	 The	 study	 of	 the	 absorption,	 distribu-
tion,	metabolism,	and	excretion	of	drugs	(ie,	what	the	body	does	to	
the	drug).
Population pharmacokinetics (PopPK):	The	study	of	the	sources	
and	correlates	of	variability	in	drug	concentrations	among	individu-
als	of	the	target	patient	population	receiving	clinically	relevant	doses	
of	a	drug	of	interest.
Prediction intervals:	Probabilistic	limits	around	a	Bayesian	pre-
dicted value.
Sparse data:	Sampling	technique	by	which	few	blood	samples	are	
drawn	at	any	time	after	a	drug	infusion.
Therapeutic window:	The	interval	between	the	lowest	effective	
and	the	highest	tolerable	(safe)	plasma	concentration	of	a	drug	in	the	
plasma/body.
Trough level:	The	lowest	plasma	level	reached	by	a	drug	between	
two	 infusions	 (usually	reached	 immediately	before	the	subsequent	
infusion,	and	also	called	pre-	dose	level).
Volume of distribution:	 The	 theoretical	 volume	 that	would	 be	
necessary	 to	 contain	 the	 total	 amount	 of	 a	 factor	 concentrate	 to	
generate	 the	 same	activity	 level	 that	 it	 is	observed	 in	 the	plasma.	
The	link	between	the	total	amount	of	factor	concentrate	in	the	body	
and	the	plasma	activity.
WAPPS-Hemo:	 Web	 Accessible	 Population	 Pharmacokinetic	
Service–Hemophilia.	A	web-	based	solution	dedicated	to	 individual	
pharmacokinetic	profiling	of	patients	with	hemophilia	treated	with	
factor	concentrates.
Wash-out:	Time	spent	off-	treatment	before	a	conventional	PK	
study	to	ensure	no	residual	factor	activity	level	generated	by	the	
factor	concentrate	 is	present	 in	 the	blood.	Usually	equal	or	 lon-
ger	than	5	times	the	anticipated	half-	life.	The	residual	measurable	
activity	level	after	an	appropriate	wash-	out	is	the	baseline	factor	
level.
Bayesian modelling:	Probabilistic	approach	 to	 forecasting	 indi-
vidual	PK	profiles	based	on	limited/sparse	samples	from	one	individ-
ual	and	previous	knowledge	from	a	population	study.
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